研究单位：[1]Department of Rheumatology Tongji Hospital,Wuhan,Hubei,China,430030内科学系风湿免疫内科[2]Wuhan Central Hospital[3]Wuhan Hospital of Traditional Chinese Medicine
研究目的：
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
